Form D · Biotechnology

Savran Technologies Inc.

Newton, MA · CIK 0001732517

Offering snapshot reported Sep 3, 2024 · SEC filing

Reported sold
$425K
Offering amount: $2M
Investors reported
30
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 16, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 3, 2024Initial$424,696No comparison30SEC filing
Mar 7, 2023Initial$304,350No comparison18SEC filing
Dec 14, 2021Initial$4,164,179No comparison52SEC filing
May 19, 2020Initial$208,000No comparison11SEC filing
Feb 27, 2019Initial$25,000No comparison1SEC filing
Oct 22, 2018Initial$1,085,500No comparison29SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-523017

Source: Form D, filed Sep 3, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nadia Altomare Director
Jeffrey Behrens Director
Jeff Behrens Director
Mark Carthy Director
Sal Daher Director
Saleh Daher Director
Yavuz Kaynar Director
Patrick Rivelli Director, Executive
Cagri Savran Director, Executive
Simon W. Turner Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
90 Bridge Street
Newton, MA, 02458